OncoCyte (NASDAQ:OCX) Earns Sell Rating from Analysts at StockNews.com

Stock analysts at StockNews.com began coverage on shares of OncoCyte (NASDAQ:OCX) in a note issued to investors on Monday. The firm set a “sell” rating on the stock.

Separately, Needham & Company LLC restated a “buy” rating and set a $4.25 price objective on shares of OncoCyte in a research report on Wednesday, November 13th.

OncoCyte Stock Performance

NASDAQ:OCX opened at $2.44 on Monday. OncoCyte has a 52-week low of $2.00 and a 52-week high of $3.98. The stock’s 50 day moving average price is $2.91 and its 200 day moving average price is $2.97.

OncoCyte (NASDAQ:OCX) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.98) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.54). The business had revenue of $0.12 million for the quarter. OncoCyte had a negative return on equity of 269.32% and a negative net margin of 6,122.29%. During the same period in the prior year, the company posted ($0.57) EPS.

Insider Buying and Selling at OncoCyte

In related news, CFO Andrea S. James acquired 33,670 shares of the company’s stock in a transaction that occurred on Wednesday, October 2nd. The stock was purchased at an average price of $2.97 per share, for a total transaction of $99,999.90. Following the transaction, the chief financial officer now owns 33,670 shares in the company, valued at $99,999.90. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Broadwood Partners, L.P. bought 1,315,339 shares of OncoCyte stock in a transaction on Wednesday, October 2nd. The stock was purchased at an average price of $2.95 per share, for a total transaction of $3,880,250.05. Following the completion of the acquisition, the insider now owns 6,244,405 shares in the company, valued at $18,420,994.75. This represents a 26.69 % increase in their position. The disclosure for this purchase can be found here. Insiders own 1.58% of the company’s stock.

Institutional Inflows and Outflows

An institutional investor recently raised its position in OncoCyte stock. Geode Capital Management LLC lifted its stake in shares of OncoCyte Co. (NASDAQ:OCX) by 12.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 103,980 shares of the company’s stock after acquiring an additional 11,289 shares during the period. Geode Capital Management LLC owned 0.62% of OncoCyte worth $296,000 as of its most recent SEC filing. Institutional investors and hedge funds own 55.35% of the company’s stock.

OncoCyte Company Profile

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.